Profile data is unavailable for this security.
About the company
Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.
- Revenue in USD (TTM)0.00
- Net income in USD-26.21m
- Incorporated2016
- Employees35.00
- LocationKiromic Biopharma Inc7707 Fannin St., Suite 140HOUSTON 77054United StatesUSA
- Phone+1 (832) 968-4888
- Fax+1 (302) 655-5049
- Websitehttps://kiromic.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regen BioPharma Inc | 236.57k | -882.60k | 946.48k | 1.00 | -- | -- | -- | 4.00 | -0.1079 | -0.1079 | 0.0297 | -0.5897 | 1.04 | -- | 3.82 | 236,570.00 | -407.33 | -104.36 | -- | -- | -- | -- | -392.01 | -275.00 | -- | -1.36 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Axim Biotechnologies Inc | 92.90k | -4.14m | 1.03m | 6.00 | -- | -- | -- | 11.05 | -0.0163 | -0.0163 | 0.0003 | -0.0324 | 0.0233 | -- | -- | 15,483.33 | -103.73 | -154.34 | -- | -390.73 | 16.94 | -- | -4,451.97 | -36,362.71 | -- | -3.14 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Novelstem International Corp | 18.00k | -1.65m | 1.22m | 15.00 | -- | -- | -- | 67.59 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -21.86m | 1.30m | 7.00 | -- | 0.122 | -- | -- | -100.63 | -100.63 | 0.00 | 10.32 | 0.00 | -- | -- | 0.00 | -84.85 | -- | -140.95 | -- | -- | -- | -- | -- | -- | -21,828.74 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -26.21m | 1.50m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Peak Bio Inc | 354.02k | -4.63m | 1.62m | -- | -- | -- | -- | 4.57 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Panbela Therapeutics Inc | 0.00 | -28.56m | 1.65m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
| Trevena Inc | 546.00k | -34.04m | 1.67m | 23.00 | -- | -- | -- | 3.05 | -47.76 | -47.76 | 0.7121 | -27.27 | 0.017 | -- | -- | 23,739.13 | -105.83 | -55.93 | -130.71 | -66.35 | -190.29 | -- | -6,233.70 | -3,134.41 | -- | -18.32 | 3.43 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Hi-Great Group Holding Co | 69.41k | -54.82k | 1.78m | -- | -- | -- | -- | 25.64 | -0.0005 | -0.0005 | 0.0007 | -0.0014 | 0.7459 | 0.6517 | -- | -- | -58.91 | -- | -- | -- | 54.26 | -- | -78.98 | -- | 0.0276 | -15.03 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| Aclarion Inc | 53.95k | -5.90m | 1.85m | 6.00 | -- | 0.91 | -- | 34.21 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 1.92m | 51.00 | -- | -- | -- | 0.0960 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Pharmagreen Biotech Inc | 4.36k | -403.84k | 1.92m | 0.00 | -- | -- | -- | 441.42 | -0.0007 | -0.0007 | 0.00001 | -0.0034 | 0.0366 | 0.2274 | 7.33 | -- | -339.07 | -523.11 | -- | -- | 54.36 | -- | -9,263.30 | -307,598.30 | 0.0004 | -2.15 | -- | -- | -- | -- | 35.03 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -9.82m | 1.95m | 8.00 | -- | 0.2695 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Dec 2023 | 0.00 | 0.00% |
